Document is current

Article History

Received: 26 June 2024

Revised: 21 November 2024

Accepted: 27 January 2025

First Online: 25 February 2025

Competing interests

: KM reports no conflicts of interest. FHH reports research funding from Novartis, BMS/Celgene, CTI and Consultancy for Novartis, BMS/Celgene, AOP Pharma, Janssen, GSK, Abbvie, Kartos, Sierra Oncology. SK reports research funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron, Imago Biosciences; advisory board honoraria and/or consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie, iOMEDICO, MPN Hub; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Kartos, Sierra Oncology, Imago Bioscience, GSK, Abbvie, MSD, iOMEDICO. RS reports no conflict of interest. JL reports no conflict of interest. FS reports advisory board and/or speaker honoraria from Abbvie, BMS/Celgene, GSK, Incyte, MorphoSys, Novartis, and Pfizer. MG reports consultancy for AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK and honoraria from AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Sierra, Lilly, GSK. MK reports no conflicts of interest. CC reports advisory board honoraria from GSK, BMS, BeiGene and AstraZeneca, honoraria from GSK, Novartis, BMS, Synlab, AOP Orphan and AstraZeneca; and other financial support (e.g. travel support) from Novartis. AH reports research support from Novartis, BMS, Incyte, Pfizer, Terns, Enliven; honoraria from Novartis and Incyte; Editor-in-Chief, Leukemia. HS reports no conflicts of interest. JRG reports honoraria from Bristol-Myers Squibb, Pfizer, Novartis, GlaxoSmithKline, Blueprint Medicines, AOP Orphan Pharmaceuticals, pharma&, Incyte; advisory board participation: Imago BioSciences, Proteros biostructures, CTI Biopharma, Bristol-Myers Squibb, Pfizer, Novartis, AbbVie, GlaxoSmithKline, Blueprint Medicines, AOP Orphan Pharmaceuticals, Incyte and travel support from Bristol-Myers Squibb, Novartis, AOP Orphan Pharmaceuticals, Incyte. HA reports consultancy for BMS, Novartis, Abbvie, AOP, GSK, Otsuka, and has received honoraria from BMS, Novartis, Abbvie, AOP, GSK, Blueprint, Stemline, MSD, Otsuka and membership on board of directors/ advisory committees from BMS, Novartis, Abbvie, AOP, and GSK, and other financial support (travel grants) from Alexion and Abbvie. HB reports honoraria from Abbvie, BMS, GSK, Lilly, MSD, Novartis, Pierre Fabre Pharma, and Servier. AR reports advisory boards and honoraria from AOP, Blueprint, Cogent, Novartis and GSK. GB reports no conflicts of interest. KK reports no conflicts of interest. THB has been a consultant for Gilead, Janssen, Merck, Novartis, and Pfizer, and has received research support from RepeatDx, Novartis and Pfizer. WH reports honoraria from Pfizer. KD reports financial relationsships or affiliations with Novartis, AOP Health, Celgene/BMS, JAZZ, Astellas, Agios, Abbvie, GSK, and MSD. SI reports advisory board honoraria from GSK, Silence Therapeutics, Pfizer, Incyte, and Novartis, honoraria from GSK, Novartis, BMS, Pfizer, Incyte, AOP Orphan; and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.